Cresco Labs (OTCMKTS:CRLBF - Get Free Report) is expected to post its quarterly earnings results before the market opens on Friday, March 21st. Analysts expect Cresco Labs to post earnings of ($0.02) per share for the quarter.
Cresco Labs Trading Down 6.0 %
Shares of OTCMKTS CRLBF opened at $0.70 on Friday. Cresco Labs has a 12-month low of $0.70 and a 12-month high of $2.60. The company has a market cap of $341.70 million, a price-to-earnings ratio of -3.50 and a beta of 1.79. The company has a current ratio of 1.97, a quick ratio of 1.39 and a debt-to-equity ratio of 1.80. The stock's 50 day simple moving average is $0.89 and its 200 day simple moving average is $1.21.
Analyst Ratings Changes
Separately, Atb Cap Markets lowered shares of Cresco Labs from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 9th. Four investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $2.50.
Get Our Latest Report on CRLBF
About Cresco Labs
(
Get Free Report)
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cresco Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.
While Cresco Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
